Granulocyte-monocyte apheresis (GMA) with Adacolumn® is an extracorporeal immunomodulatory therapy option that selectively depletes circulating activated granulocytes and monocytes. This approach aims to control intestinal inflammation and represents a steroid-sparing strategy for patients with inflammatory bowel disease (IBD) who are steroid-dependent, intolerant, or refractory to conventional and/or advances therapies. The GRACE study aimed to assess the efficacy, safety, and real-world use of GMA in adult patients with ulcerative colitis (UC) or Crohn’s disease (CD) in routine clinical practice in Spain. This national, multicentre, non-interventional post-marketing ongoing clinical follow-up study enrolled 148 patients with UC or CD treated with GMA (Adacolumn®). This interim analysis shows data collected at baseline and follow-up visits up to six months post-treatment. The primary endpoint of this interim analysis was the proportion of patients achieving steroid-free clinical remission six months after completion of the GMA induction, defined as a Mayo score ≤2 for UC and a Harvey–Bradshaw Index (HBI) ≤4 for CD. Secondary endpoints included the evaluation of clinical response, safety outcomes, and patterns of GMA use. The study population comprised a total of 148 patients (88.5% UC and 11.5% CD) with a mean disease duration of 9.7 and 8.7 years, respectively. Most had moderate-to-severe disease activity (79,4%) and prior exposure to steroids (82.4%), immunosuppressants (50.0%), biologics (68.9%) and JAK inhibitors (19.6%). One month after completion of GMA treatment, overall steroid-free clinical remission was achieved in 33,9% of patients (33% UC, 40% CD). At 6 months, 30,5% of patients remained in steroid-free clinical remission. The highest steroid-free remission rates were observed among patients not receiving concomitant advanced therapies; with 47,1% and 56% at 1 and 6 months, respectively. GMA was well tolerated; 88.5% of adverse events were mild or moderate, and no serious adverse events were related to the device or procedure. In this real-world interim analysis, GMA was primarily used in complex, treatment-refractory IBD patients, mostly as an adjunct to biologic therapy. Despite the challenging clinical scenario of this population, GMA achieved clinically meaningful rates of steroid-free remission at six months, confirming its favorable safety and tolerability profile. These findings highlight the steroid-sparing effect of GMA, reinforcing its role as a valuable therapeutic option within the comprehensive management of refractory UC and CD. Conflict of interest: Dr. Rodríguez-Lago, Iago: Financial support for traveling and educational activities from or has served as an advisory board member for Abbvie, Adacyte, Alfasigma, Biogen, Chiesi, Faes Farma, Ferring, Fresenius Kabi, Galapagos, Johnson & Johnson, Eli Lilly, Mirum Pharmaceuticals, Merck, Pfizer, Roche, Takeda, and Tillotts Pharma. Research support from AbbVie. Supported by a research grant from Gobierno Vasco-Eusko Jaurlaritza (Grant No 2020111061 and 2023222006). Cabriada Nuno, José Luis: No conflict of interest Vicuña Arregui, Miren: No conflict of interest Leo, Eduardo: The author declares receiving grants or fees for scientific activities, presentations, or as a scientific advisor for MSD, Pfizer, Abbvie, Takeda, Janssen, Tillotts Pharma, Shire Pharmaceuticals, Ferring, Dr. Falk Pharma, Lilly, Adacyte, and Otsuka Pharmaceutical. Iglesias Flores, Eva: has served as a speaker, consultant and advisory member for or has received research funding from AbbVie, Janssen, Takeda, Gillead, Celgene, Pfizer, Lilly, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, and Adacyte, Domènech Moral, Eugeni: Personal Fees: I have served as a speaker, or has received research or education funding or advisory fees from AbbVie, Adacyte Therapeutics, Biogen, Celltrion, Gilead, Janssen, Kern Pharma, MSD, Pfizer, Roche, Samsung, Takeda, Tillots. Other: I have served as a speaker, or has received research or education funding or advisory fees from AbbVie, Adacyte Therapeutics, Alfasigma/Galapagos Biogen, Celltrion, Ferring, Gilead, GoodGut, Imidomics, Janssen, Kern Pharma, Lilly, MSD, Pfizer, Roche, Takeda, Tillots. Moraleja-Yudego, Irene: The author declares receiving financial support for traveling and educational activities from or has served as an advisory board member for Adacyte. Boscá Watts, Marta Maia: The author declares to have paticipated in presentations / advisory boards / research promoted by: MSD, Ferring, Abbvie, Janssen, Biogen, Pfizer, Galápagos, Otsuka, Kernpharma and Takeda. Calvo Iñiguez, María: The authors declares receiving support for educational purposes from Abbvie, Takeda, Adacyte, Janssen, Lilly and Kern Pharma. Abanades Tercero, María: Abbvie, Adacyte, Ferring. Todos ellos para financiación de congresos/cursos. Moralejo Lozano, Óscar: I have received educational funding from Abbvie, Johnson & Johnson, Takeda, Kern Pharma, Alfasigma, Pfizer, Lilly, Sandoz, Dr. Falk Pharma, Ferring, and Tillotts. I have also served as a speaker for Abbvie, Takeda, Alfasigma, and Lilly. Rancel Medina, Francisco Jose: No conflict of interest Bastida Paz, Guillermo: I declare that I have received fees for lectures, consulting, research, or other collaborations from the following laboratories: Abbvie, J & J, Kern, Lilly, and GALAPAGOS. Herrera De Guise, Claudia Maria: No conflict of interest Hernández Ramirez, Vicente: Vicent Hernandez has served as consultant, has served as speaker, has received travel support or research funding from MSD, AbbVie, Ferring, Dr. Falk Pharma, Tillotts Pharma, Pfizer, Takeda, Janssen, KernPharma Biologics, Adacyte, Sandoz, FAES Farma, Galapagos, Lilly and Casen-Recordati Sánchez, Damián: The author confirms receiving assistance for attending conferences and training sessions from Adacyte, Abbvie, Janssen, and Takeda, and personal fees for training talks from Abbvie and Janssen. Viejo Almazor, Alejandro: No conflict of interest Fradejas Salazar, Paola María: No conflict of interest Suarez Ferrer, Cristina Julia: The author declares receiving speaker or researcher fee from: Ferring, FAES, Abbvie, Jannsen, Pfizer, Takeda, Thillots, Kher, Chiesi, Aldacyte, Lilly. Blasco Comenarejo, Maria del Mar: The author declares receiving Falk funding for conference. Ceballos Santos, Daniel: No conflict of interest Quílez Pérez, Lucía: No conflict of interest Rull Murillo, Nuria: No conflict of interest Muñoz, Margarita: No conflict of interest Arribas Del Campo, Sonia: The author declares receiving fees from Abbvie, Galápagos, Tillots. Madero Velázquez, Lucía: None Huguet, José María: The auhtor has participated in educational activities, research projects, scientific meetings or advisory boards sponsored by Abbvie, Biogen, Faes Farma, Ferring, Janssen, Kern Pharma, Merck Sharp Dohme (MSD), Sandoz, Takeda, and Vifor Pharma Fernández Pérez, Francisco Jose: The author received speaker fees from: Adacyte, Abbvie, Ferring, Shire. The author had courses organized with the collaboration of: Johnson & Johnson, Abbvie, Lilly, Pfizeer, Ferring. Soria López, Estela: No conflict of interest Reygosa, María Cristina: Cristina Reygosa has served as a speaker, or has received education funding from Abbvie, Takeda, Pfizer, Janssen and Ferring Hernandez Camba, Alejandro: I have served as a speaker or has received research or education funding or advisory fees from Lilly, Takeda, J and J, FAES Pharma, Falk, Abbvie, Adacyte Therapeutics, Tyllots, Ferring, Kern Pharma, Alfasigma and Chiesi. Zapico Fernandez, Pablo: P.Z. is a full-time employee od Adacyte Therapeutics. Ginard Vicens, Daniel: No conflicts
Background: Topical corticosteroids are essential for the management of inflammatory skin diseases but optimizing efficacy whilst minimizing adverse effects remains critical. Methylprednisolone aceponate (MPA) is a fourth-generation, non-halogenated corticosteroid developed to enhance local activity with limited systemic exposure. This review summarizes its pharmacology, clinical efficacy and safety. Methods: A PubMed search (1990–2025) was conducted to identify relevant studies on MPA in inflammatory dermatoses. Results: MPA’s di-esterified structure and 6α-methyl modification provide potent anti-inflammatory activity with low atrophogenic potential. It is activated within the skin to a highly active metabolite and rapidly inactivated systemically, resulting in minimal systemic absorption. Clinically, MPA provides rapid pruritus relief and high clearance rates in eczematous conditions, including atopic, contact and seborrheic dermatitis. Once-daily application is generally sufficient, supporting adherence. Its availability in multiple formulations allows treatment to be tailored to lesion type and anatomical site. Longterm use is associated with a low risk of skin atrophy or hypothalamic–pituitary–adrenal axis suppression, and allergic sensitization is rare. Conclusions: MPA offers an effective and well-tolerated option for acute and maintenance management of inflammatory skin diseases. Download the Plain Language Summary of this article: https://www.drugsincontext.com/plain-language-summaries/plain-language-summary-revisiting-methylprednisolone-aceponate-efficacy-safety-and-current-positioning
Variant transthyretin amyloidosis (A-ATTRv) caused by the p.Val50Met mutation is a multisystemic disease with marked geographic variability. Mallorca represents one of the main endemic foci in Europe. Although disease-modifying therapies have improved prognosis, real-world data on hospitalization patterns and causes of death remain limited. We conducted a retrospective observational study including deceased patients with A-ATTRv V30M from Mallorca up to November 2024. Demographic characteristics, comorbidity burden, neurological stage, hospital admissions and causes of death were analyzed using clinical records. Fifty-five patients (60% male) were included, with a median age at diagnosis of 68.5 years (IQR 59–75). Most patients (78.2%) presented a mixed neurological and cardiac phenotype. During follow-up, 41.8% experienced five or more emergency department visits or hospital admissions. Infectious complications, particularly urinary tract infections, were the most frequent cause of hospitalization, followed by cardiovascular events, mainly heart failure. Cardiovascular causes accounted for the largest proportion of deaths (29.1%), predominantly heart failure and sudden death. Median overall from diagnosis to death was 70 months (IQR 37–108). In this endemic A-ATTRv V30M cohort, cardiovascular complications—especially heart failure—were the main causes of mortality and a major driver of hospitalization, highlighting the importance of early multidisciplinary management.
Background. Sepsis is a leading, time-dependent cause of in-hospital death, and guidelines now prioritize organized care such as code-sepsis protocols. Yet little is known about the long-term activity, organization and outcomes of permanent, hospital-scale programs. We characterized the activity of a hospital-wide multidisciplinary sepsis unit (MSU) over thirteen years and evaluated mortality trends. Methods. Retrospective cohort study using the registry of a hospital-wide MSU (2011-2023). The analysis unit was the sepsis event. Activity, referral pathways, interventions, follow-up and mortality were analyzed; temporal trends used multivariable logistic regression and standardized mortality ratios (SMR). Results. The unit attended 10,874 patients across 15,723 events and 50,925 consultations (median age 67; 59.3% men), referred mainly through the sepsis code (45.0%) and, increasingly, proactive early-warning detection (15.2%). An antibiotic change was recommended in 57.2% of events, and 89.8% of all suggested changes were implemented. Follow-up was sustained (median 3 visits; 61.8%). In-hospital mortality was 7.6%, and 11.8% in protocol-confirmed sepsis. Crude mortality did not fall, but severity rose (organ dysfunctions 1.67 to 2.72; septic shock 8 to 13%; both p < 0.001) with stable age; after adjustment the calendar-year effect disappeared (adjusted OR 1.00/year, p = 0.70) and the SMR stayed near 1.0, including pandemic years. Age, ICU admission (OR 2.65) and organ-dysfunction count (OR 1.37) independently predicted death. Conclusions. Over thirteen years, this hospital-wide MSU delivered large-scale, multi-channel, longitudinal care to an increasingly severe population while maintaining stable risk-adjusted mortality, supporting the long-term feasibility of a model integrating early detection, multidisciplinary decision-making, antimicrobial stewardship and follow-up.
Importance: Sepsis is a leading cause of in-hospital mortality, where timely and accurate diagnosis is critical yet frequently delayed. Whether large language models (LLMs) can diagnose sepsis reliably -- and whether they do so fairly, consistently, and with well-calibrated confidence -- remains unknown. Objective: To evaluate the diagnostic capabilities of LLMs on standardised sepsis vignettes before and after biomarker disclosure, benchmarked against physicians, and to characterise their robustness, stability, bias and confidence calibration. Design: Retrospective in-silico study based on six anonymised real cases spanning the diagnostic spectrum from no infection to septic shock. For each case, the reference-standard diagnosis was assigned, following the Sepsis-3 framework. Each case was evaluated under a two-stage (pre- and post-biomarker disclosure) protocol. To assess potential demographic bias, every case was additionally presented while systematically varying the patient's sex, age, and language. Setting and Participants: Five locally deployed LLMs (DeepSeek-4, Qwen3.8-27B, its quantised variant, Gemma-4-31B, and the domain-specific MedGemma) were evaluated in a controlled evaluation pipeline and compared with responses from 353 clinicians, using identical clinical vignettes. Main Outcomes and Measures: Diagnostic accuracy before/after biomarker disclosure, per-vignette error, sensitivity to demographic attributes (diagnosis-change rate) and its directional component, reproducibility across repetitions and confidence calibration. Results: Before biomarkers, model accuracy ranged 40-67\%, comparable to physicians (57\%). After disclosure, physician accuracy was 61\%, exceeded by Qwen3.8-27B (91\%), its quantised variant (86\%) and Gemma-4-31B (83\%); DeepSeek-4 reached 64\% and MedGemma 56\%, the only model below physicians. Biomarkers rescued confirmatory cases (pancreatitis-associated sepsis), whereas post-surgical sepsis remained difficult for models and physicians alike. Quantisation cost only 5 accuracy points. Patient sex and age showed no directional bias, and language was the only bias. Gemma-4-31B was the most reproducible model, the Qwen models were the most accurate and best calibrated, and MedGemma the least. Conclusions and Relevance: LLMs, including quantised variants, can provide accurate informed decision support for sepsis, surpassing physicians once laboratory data are available. However, robustness, calibration, and language fairness varied independently of accuracy and should guide model selection and clinical validation. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study protocol was reviewed and approved by the Comite Etico Cien- tifico de la Universidad Finis Terrae (Santiago, Chile) on 17 November 2025 (plenary session no. 23; protocol ID 25-114). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors